Abhijeet Kumar
Hematology & Oncology · Baltimore, MDNPI 1134409923
Payments from drug & device makers
Across 987 payments — averaging $2209.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$700K
- Incyte Corporation$263K
- Boehringer Ingelheim$210K
- Regeneron$169K
- Pharmacyclics LLC, An Abbvie Company$167K
- Exelixis Inc.$118K
- plus $554K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 289 | $700,064 |
| Incyte Corporation | 173 | $262,831 |
| Boehringer Ingelheim | 22 | $209,878 |
| Regeneron | 36 | $168,962 |
| Pharmacyclics LLC, An Abbvie Company | 153 | $167,107 |
| Exelixis Inc. | 41 | $118,075 |
| ADC Therapeutics America, Inc. | 38 | $105,073 |
| Beigene, Ltd. | 55 | $75,233 |
| Morphosys AG | 7 | $63,505 |
| Genentech, Inc. | 13 | $59,440 |
| Beone Medicines USA, Inc. | 21 | $54,799 |
| Acerta Pharma LLC | 3 | $44,579 |
| TG Therapeutics, Inc. | 24 | $39,236 |
| Epizyme, Inc. | 42 | $38,746 |
| Genmab BV | 12 | $29,220 |
| AstraZeneca | 30 | $19,967 |
| Beigene USA, Inc. | 6 | $13,346 |
| Kyowa Kirin, Inc. | 7 | $3,850 |
| Astrazeneca UK Limited | 1 | $3,438 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $2,827 |
| Boehringer Ingelheim International GmbH | 1 | $278 |
| Seagen Inc. | 1 | $99 |
| Pfizer | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Genentech USA, Inc. | 1 | $37 |
| Sanofi | 1 | $29 |
| Geron Corporation | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Tempus AI, Inc | 1 | $20 |
| Secura Bio, Inc. | 1 | $15 |
How this compares
$2,180,792 in reported general payments places this provider in the 90th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Baltimore
- Dan ZandbergBaltimore$9.9M
- Ani BalmanoukianBaltimore$6.6M
- Mark MarkowskiBaltimore$5.9M
- Ivana GojoBaltimore$5M
- Suman RaoBaltimore$4.2M
- Patrick FordeBaltimore$4.1M
- Mehmet KocogluBaltimore$3.5M
- Noah HahnBaltimore$3.4M
- Seung Tae LeeBaltimore$2.7M
- Maria BaerBaltimore$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.